Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eye injection aims to halt vision loss in dry AMD

NCT ID NCT06087458

Disease control Sponsor: Perceive Biotherapeutics, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 18, 2026 · Updated 2 times

Summary

This early-stage trial is testing a new drug called VOY-101 for people with advanced dry age-related macular degeneration (AMD) and geographic atrophy, a condition that causes blind spots. The drug is injected into the eye and aims to slow damage to the retina and preserve vision. The study will enroll 60 participants aged 60 and older to evaluate safety and effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
VOY-101 (a biologic drug injected into the eye)
What this could lead to
If successful, this could lead to a treatment that slows or stops the progression of geographic atrophy in dry age-related macular degeneration, preserving vision.
What could go wrong
This is an early-phase trial with only 60 participants, so results may not apply to everyone. The drug is injected into the eye, which carries risks like infection or inflammation, and it may not slow vision loss as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2023

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Are ≥60 years of age at the time of consent. * Are willing and able to understand and provide written informed consent. * Are willing and able to return for scheduled treatment and follow-up examinations. * Are able to undergo ETDRS BCDVA testing and ophthalmic imaging. * Well-demarcated GA secondary to AMD in the absence of MNV and in the absence of history of MNV for both eyes. * Absence of signs of non-exudative MNV. * Additional Ocular Inclusion Criteria for both eyes. * Meet certain genotype criteria for risk of AMD. Exclusion Criteria: * Are women of childbearing potential (WOCBP) and are pregnant or unwilling to use and document use of effective contraception for the duration of the study. * Additional Systemic, Ocular, and Genetic Exclusion Criteria.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Age-related macular degeneration are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

age-related macular degeneration dry age related macular degeneration Geographic Atrophy macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Age-related macular degeneration Geographic atrophy Non-neovascular age-related macular degeneration Non-neovascular AMD

Contacts and locations

Locations

  • Austin Research Center for Retina

    Austin, Texas, 78705, United States

  • Black Hills Regional Eye Institute

    Rapid City, South Dakota, 57701, United States

  • Cerulea Clinical Trials

    East Melbourne, Victoria, 3002, Australia

  • Mid Atlantic Retina

    Cherry Hill, New Jersey, 08034, United States

  • Ophthalmic Consultants of Boston

    Boston, Massachusetts, 02114, United States

  • Rambam Medical Center

    Haifa, Israel

  • Retina Center of Texas

    Southlake, Texas, 76092, United States

  • Retina Consultants San Diego

    Poway, California, 92064, United States

  • Retina Macula Institute of AZ

    Scottsdale, Arizona, 85255, United States

  • Retina Northwest

    Portland, Oregon, 97221, United States

  • Retinal Consultants Medical Group

    Sacramento, California, 95825, United States

  • Star Retina

    Fort Worth, Texas, 76132, United States

  • Sydney Retina Clinic and Day Surgery

    Sydney, New South Wales, 2000, Australia

  • Tel-Aviv Sourasky Medical Center, Ophthalmology Division

    Tel Aviv, 64239, Israel

  • The Retina Institute

    St Louis, Missouri, 63128, United States

  • University of Utah John A. Moran Eye Center

    Salt Lake City, Utah, 84132, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.